Actualités Medivir AB - 0GP7 | Actions London Stock Exchange

Votre Hub pour des idées et discussions en direct en temps réel

Medivir to present clinical pharmacokinetic data at EASL Liver Cancer Summit, further supporting the continued development of fostrox

Medivir to present clinical pharmacokinetic data at EASL Liver Cancer Summit, further supporting the continued development of fostrox PR...

Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study

Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study PR...

Fostrox + Lenvima demonstrates further improvement in durable clinical benefit in HCC, supporting the accelerated development plan

Fostrox + Lenvima demonstrates further improvement in durable clinical benefit in HCC, supporting the accelerated development plan PR...

Medivir have agreed with Lonza to manufacture a fostrox GMP campaign, to be tested in 2L HCC with intent to commercialize via accelerated approval

Medivir have agreed with Lonza to manufacture a fostrox GMP campaign, to be tested in 2L HCC with intent to commercialize via accelerated...

Medivir's partner IGM Biosciences announces strategic pipeline prioritization to extend its cash runway

Medivir's partner IGM Biosciences announces strategic pipeline prioritization to extend its cash runway PR Newswire STOCKHOLM, Dec. 6, 2023...

Medivir to present at the Carlsquare Equity Research Investor Day

Medivir to present at the Carlsquare Equity Research Investor Day PR Newswire STOCKHOLM, Dec. 6, 2023 STOCKHOLM, Dec. 6, 2023 /PRNewswire/...

Bulletin from Extraordinary General Meeting in Medivir AB (publ)

Bulletin from Extraordinary General Meeting in Medivir AB (publ) PR Newswire STOCKHOLM, Dec. 1, 2023 STOCKHOLM, Dec. 1, 2023 /PRNewswire/...

Medivir announces updated formulation of fostrox, critical to support planned study with accelerated approval intent in second line HCC

Medivir announces updated formulation of fostrox, critical to support planned study with accelerated approval intent in second line HCC PR...

Medivir to present at the Redeye Life Science Day

Medivir to present at the Redeye Life Science Day PR Newswire STOCKHOLM, Nov. 22, 2023 STOCKHOLM, Nov. 22, 2023 /PRNewswire/ -- Medivir AB...

Medivir to present at the Erik Penser Bank Company Event

Medivir to present at the Erik Penser Bank Company Event PR Newswire STOCKHOLM, Nov. 21, 2023 STOCKHOLM, Nov. 21, 2023 /PRNewswire/ -- Medivir AB...

Medivir to present clinical data at ASCO-GI with fostrox + Lenvima in HCC and shares positive response from Type D meeting with FDA

Medivir to present clinical data at ASCO-GI with fostrox + Lenvima in HCC and shares positive response from Type D meeting with FDA PR...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Medivir AB (0GP7)

Votre Hub pour des idées et discussions en direct en temps réel

Medivir AB (0GP7) Actualités

Medivir to present clinical pharmacokinetic data at EASL Liver Cancer Summit, further supporting the continued development of fostrox

Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study

Fostrox + Lenvima demonstrates further improvement in durable clinical benefit in HCC, supporting the accelerated development plan

Medivir have agreed with Lonza to manufacture a fostrox GMP campaign, to be tested in 2L HCC with intent to commercialize via accelerated approval

Medivir's partner IGM Biosciences announces strategic pipeline prioritization to extend its cash runway

Medivir to present at the Carlsquare Equity Research Investor Day

Bulletin from Extraordinary General Meeting in Medivir AB (publ)

Medivir announces updated formulation of fostrox, critical to support planned study with accelerated approval intent in second line HCC

Medivir to present at the Redeye Life Science Day

Medivir to present at the Erik Penser Bank Company Event

Medivir to present clinical data at ASCO-GI with fostrox + Lenvima in HCC and shares positive response from Type D meeting with FDA

Notice of Extraordinary General Meeting in Medivir AB (publ)

MEDIVIR AB - INTERIM REPORT JANUARY - SEPTEMBER 2023

Medivir to report new and updated data from ongoing phase 2a HCC study as part of its Q3 report on Friday

Nomination Committee of Medivir appointed

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Medivir AB (0GP7)

Votre Hub pour des idées et discussions en direct en temps réel

Medivir AB (0GP7) Actualités

Medivir to present clinical pharmacokinetic data at EASL Liver Cancer Summit, further supporting the continued development of fostrox

Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study

Fostrox + Lenvima demonstrates further improvement in durable clinical benefit in HCC, supporting the accelerated development plan

Medivir have agreed with Lonza to manufacture a fostrox GMP campaign, to be tested in 2L HCC with intent to commercialize via accelerated approval

Medivir's partner IGM Biosciences announces strategic pipeline prioritization to extend its cash runway

Medivir to present at the Carlsquare Equity Research Investor Day

Bulletin from Extraordinary General Meeting in Medivir AB (publ)

Medivir announces updated formulation of fostrox, critical to support planned study with accelerated approval intent in second line HCC

Medivir to present at the Redeye Life Science Day

Medivir to present at the Erik Penser Bank Company Event

Medivir to present clinical data at ASCO-GI with fostrox + Lenvima in HCC and shares positive response from Type D meeting with FDA

Notice of Extraordinary General Meeting in Medivir AB (publ)

MEDIVIR AB - INTERIM REPORT JANUARY - SEPTEMBER 2023

Medivir to report new and updated data from ongoing phase 2a HCC study as part of its Q3 report on Friday

Nomination Committee of Medivir appointed

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Sign up for FREE and get:

Supprimer les publicités